Problem

Orthopedic surgery still has a costly preoperative-planning bottleneck. Joint-replacement plans can take two to five business days, while acute and complex fractures often lack comparable planning workflows, forcing surgeons to determine treatment during the operation. That can create trial and error, wasted operating-room time, wrong implant selection, complications, and revision surgeries. The broader economic burden is substantial: fractures are associated with an estimated annual cost of €37.5 billion in Europe.

Mango Medical’s clearest use case is patient-specific planning for complex, time-sensitive acute fractures, a category the company estimates at roughly 15 million surgeries annually. Its initial commercial focus also includes shoulder-replacement planning, where faster planning could give surgeons a detailed plan before entering the operating room rather than requiring them to improvise around difficult anatomy.

Product / Service

Mango Medical is developing agentic surgical-planning AI that accepts CT scans and X-rays, reconstructs the patient’s anatomy, and recommends a procedure-ready plan covering factors such as implant sizes and surgical approach. The company describes an API-based model in which orthopedic implant companies submit imaging and receive a complete plan, with outputs delivered in seconds or minutes instead of the multiple business days associated with specialized planning teams. Its broader software vision includes patient-specific fracture reconstructions and digital planning in under three minutes.

The intended benefit is to make complex cases more predictable while reducing the surgeon’s cognitive load, planning interruptions, and dependence on intraoperative trial and error. By making planning effectively instantaneous, Mango also aims to support scenario simulation and downstream technologies such as robotic surgery and custom 3D-printed guides or implants, although the available evidence describes these as intended applications rather than proven clinical outcomes.

Market

Mango competes in AI-enabled orthopedic surgical planning and the broader medtech market for digital templating, fracture reconstruction, and personalized preoperative decision support. The opportunity is large: the company cites approximately 30 million orthopedic surgeries annually, including about 10 million joint replacements and 15 million acute fractures. PitchBook identifies OSORA medical as a competitor, while Brainlab’s TraumaCad is an established adjacent alternative offering digital orthopedic templating, implant libraries, measurement tools, automated calibration, PACS integration, and pre-surgical reports.

The company appears to be in early commercialization rather than at scale. Y Combinator lists Mango Medical as an active Winter 2026 company founded in 2024, with a three-person team, an eight-figure letter of intent from a top orthopedic company, and an ongoing pursuit of FDA 510(k) clearance. Public sources do not disclose a revenue figure; one database labels a 2025 financing record as generating revenue, so Mango should not be classified definitively as pre-revenue, but the disclosed traction is still primarily an LOI and regulatory progress rather than demonstrated recurring sales.